20.06.2014 • News

Recipharm and CTC in Clinical Trial Collaboration

CTC Clinical Trial Consultants of Uppsala, Sweden, and compatriot Recipharm Pharmaceutical Development of Solna, Stockholm, Sweden, have begun a collaboration to offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material.

The scope of the cooperation will extend to planning, performing and evaluation of the clinical trial.

Maria Lundberg, general manager Recipharm Pharmaceutical Development, said the link-up will allow the two companies to offer customers faster and more cost-efficient phase I studies. "We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies."

CTC has "excellent experience" in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset), Lundberg noted.

Beyond shortening project timelines, Bengt Dahlström, CEO of CTC Clinical Trial said the systematic integrated approach will help the companies to obtain more information on the desirable properties of the drug formulation.

"Adaptive design," he said, "is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol."

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.